Biodexa Historical Balance Sheet

BDRX Stock

1.29 0.20 13.42%

Trend analysis of Biodexa Pharmaceticals balance sheet accounts such as Other Current Liab of 2.5 M, Total Current Liabilities of 3.8 M or Total Stockholder Equity of 4 M provides information on Biodexa Pharmaceticals' total assets, liabilities, and equity, which is the actual value of Biodexa Pharmaceticals to its prevalent stockholders. By breaking down trends over time using Biodexa Pharmaceticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Biodexa Pharmaceticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Biodexa Pharmaceticals is a good buy for the upcoming year.

Biodexa Pharmaceticals Inventory

(601,920)

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biodexa Pharmaceticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.

About Biodexa Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Biodexa Pharmaceticals at a specified time, usually calculated after every quarter, six months, or one year. Biodexa Pharmaceticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Biodexa Pharmaceticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Biodexa currently owns. An asset can also be divided into two categories, current and non-current.

Biodexa Pharmaceticals Balance Sheet Chart

At this time, Biodexa Pharmaceticals' Capital Stock is fairly stable compared to the past year. Current Deferred Revenue is likely to rise to about 1.1 M in 2025, whereas Total Assets are likely to drop slightly above 9 M in 2025.

Total Assets Other Current Liab Total Current Liabilities Property Plant And Equipment Net

Total Assets

Total assets refers to the total amount of Biodexa Pharmaceticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Biodexa Pharmaceticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Biodexa Pharmaceticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Biodexa Pharmaceticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Most accounts from Biodexa Pharmaceticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Biodexa Pharmaceticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biodexa Pharmaceticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.At this time, Biodexa Pharmaceticals' Capital Stock is fairly stable compared to the past year. Current Deferred Revenue is likely to rise to about 1.1 M in 2025, whereas Total Assets are likely to drop slightly above 9 M in 2025.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	1.3M	5.0M	4.5M	2.5M
Total Assets	5.5M	10.5M	9.5M	9.0M

Other Current Liab Total Assets

Biodexa Pharmaceticals balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Short Long Term Debt Total	Net Receivables	Short Term Debt	Common Stock	Inventory	Net Tangible Assets	Common Stock Shares Outstanding
Total Assets		0.35	0.67	0.99	0.84	-0.72	0.18	0.7	0.81	0.96	0.59	-0.32	0.81	0.66	0.66	-0.07	0.72	0.88	0.94	0.28	0.63	-0.29	-0.35	0.46	-0.34	-0.33
Other Current Liab	0.35		0.84	0.25	0.24	-0.06	0.23	0.15	0.02	0.48	-0.22	-0.34	0.02	0.35	0.12	-0.2	0.66	0.07	0.44	0.12	0.68	0.11	0.0	0.26	-0.06	0.06
Total Current Liabilities	0.67	0.84		0.55	0.6	-0.21	0.25	0.65	0.28	0.77	0.3	-0.33	0.28	0.65	0.47	-0.2	0.91	0.37	0.71	0.42	0.76	0.05	-0.17	0.42	-0.26	-0.12
Total Stockholder Equity	0.99	0.25	0.55		0.82	-0.79	0.12	0.63	0.86	0.91	0.56	-0.28	0.86	0.55	0.62	-0.01	0.6	0.92	0.9	0.18	0.58	-0.36	-0.33	0.4	-0.3	-0.31
Property Plant And Equipment Net	0.84	0.24	0.6	0.82		-0.38	0.22	0.79	0.53	0.87	0.69	-0.43	0.53	0.63	0.86	-0.14	0.66	0.63	0.79	0.53	0.56	-0.12	-0.54	0.62	-0.45	-0.54
Net Debt	-0.72	-0.06	-0.21	-0.79	-0.38		-0.03	-0.29	-0.97	-0.51	-0.23	0.05	-0.97	-0.14	-0.1	-0.08	-0.19	-0.93	-0.55	0.16	-0.24	0.39	0.11	-0.12	0.07	0.05
Retained Earnings	0.18	0.23	0.25	0.12	0.22	-0.03		0.14	0.06	0.21	0.13	-0.91	0.06	0.41	0.35	-0.96	0.35	0.06	0.2	0.5	-0.02	0.86	-0.69	0.73	-0.71	-0.67
Accounts Payable	0.7	0.15	0.65	0.63	0.79	-0.29	0.14		0.46	0.72	0.82	-0.13	0.46	0.7	0.69	-0.06	0.73	0.53	0.65	0.64	0.4	-0.06	-0.39	0.41	-0.38	-0.39
Cash	0.81	0.02	0.28	0.86	0.53	-0.97	0.06	0.46		0.61	0.43	-0.08	1.0	0.31	0.26	0.05	0.32	0.99	0.63	0.05	0.34	-0.38	-0.19	0.22	-0.17	-0.14
Non Current Assets Total	0.96	0.48	0.77	0.91	0.87	-0.51	0.21	0.72	0.61		0.58	-0.38	0.61	0.74	0.76	-0.13	0.83	0.71	0.98	0.33	0.69	-0.21	-0.35	0.5	-0.37	-0.34
Non Currrent Assets Other	0.59	-0.22	0.3	0.56	0.69	-0.23	0.13	0.82	0.43	0.58		-0.14	0.43	0.61	0.78	-0.07	0.48	0.48	0.57	0.59	0.14	-0.08	-0.39	0.27	-0.46	-0.4
Other Assets	-0.32	-0.34	-0.33	-0.28	-0.43	0.05	-0.91	-0.13	-0.08	-0.38	-0.14		-0.08	-0.42	-0.52	0.87	-0.38	-0.12	-0.35	-0.47	-0.19	-0.7	0.73	-0.8	0.71	0.73
Cash And Short Term Investments	0.81	0.02	0.28	0.86	0.53	-0.97	0.06	0.46	1.0	0.61	0.43	-0.08		0.31	0.26	0.05	0.32	0.99	0.63	0.05	0.34	-0.38	-0.19	0.22	-0.17	-0.14
Non Current Liabilities Total	0.66	0.35	0.65	0.55	0.63	-0.14	0.41	0.7	0.31	0.74	0.61	-0.42	0.31		0.68	-0.36	0.89	0.38	0.74	0.7	0.44	0.14	-0.48	0.55	-0.48	-0.48
Other Current Assets	0.66	0.12	0.47	0.62	0.86	-0.1	0.35	0.69	0.26	0.76	0.78	-0.52	0.26	0.68		-0.3	0.61	0.36	0.74	0.54	0.3	0.07	-0.59	0.55	-0.57	-0.58
Other Stockholder Equity	-0.07	-0.2	-0.2	-0.01	-0.14	-0.08	-0.96	-0.06	0.05	-0.13	-0.07	0.87	0.05	-0.36	-0.3		-0.31	0.05	-0.12	-0.46	0.08	-0.87	0.63	-0.65	0.76	0.62
Total Liab	0.72	0.66	0.91	0.6	0.66	-0.19	0.35	0.73	0.32	0.83	0.48	-0.38	0.32	0.89	0.61	-0.31		0.41	0.79	0.6	0.67	0.09	-0.31	0.52	-0.4	-0.28
Total Current Assets	0.88	0.07	0.37	0.92	0.63	-0.93	0.06	0.53	0.99	0.71	0.48	-0.12	0.99	0.38	0.36	0.05	0.41		0.71	0.11	0.44	-0.4	-0.23	0.27	-0.21	-0.18
Intangible Assets	0.94	0.44	0.71	0.9	0.79	-0.55	0.2	0.65	0.63	0.98	0.57	-0.35	0.63	0.74	0.74	-0.12	0.79	0.71		0.24	0.57	-0.25	-0.3	0.42	-0.34	-0.29
Short Long Term Debt Total	0.28	0.12	0.42	0.18	0.53	0.16	0.5	0.64	0.05	0.33	0.59	-0.47	0.05	0.7	0.54	-0.46	0.6	0.11	0.24		0.31	0.46	-0.55	0.64	-0.55	-0.56
Net Receivables	0.63	0.68	0.76	0.58	0.56	-0.24	-0.02	0.4	0.34	0.69	0.14	-0.19	0.34	0.44	0.3	0.08	0.67	0.44	0.57	0.31		-0.24	0.03	0.39	-0.03	0.03
Short Term Debt	-0.29	0.11	0.05	-0.36	-0.12	0.39	0.86	-0.06	-0.38	-0.21	-0.08	-0.7	-0.38	0.14	0.07	-0.87	0.09	-0.4	-0.25	0.46	-0.24		-0.51	0.53	-0.52	-0.5
Common Stock	-0.35	0.0	-0.17	-0.33	-0.54	0.11	-0.69	-0.39	-0.19	-0.35	-0.39	0.73	-0.19	-0.48	-0.59	0.63	-0.31	-0.23	-0.3	-0.55	0.03	-0.51		-0.57	0.81	0.94
Inventory	0.46	0.26	0.42	0.4	0.62	-0.12	0.73	0.41	0.22	0.5	0.27	-0.8	0.22	0.55	0.55	-0.65	0.52	0.27	0.42	0.64	0.39	0.53	-0.57		-0.44	-0.63
Net Tangible Assets	-0.34	-0.06	-0.26	-0.3	-0.45	0.07	-0.71	-0.38	-0.17	-0.37	-0.46	0.71	-0.17	-0.48	-0.57	0.76	-0.4	-0.21	-0.34	-0.55	-0.03	-0.52	0.81	-0.44		0.78
Common Stock Shares Outstanding	-0.33	0.06	-0.12	-0.31	-0.54	0.05	-0.67	-0.39	-0.14	-0.34	-0.4	0.73	-0.14	-0.48	-0.58	0.62	-0.28	-0.18	-0.29	-0.56	0.03	-0.5	0.94	-0.63	0.78

Click cells to compare fundamentals

Biodexa Pharmaceticals Account Relationship Matchups

Biodexa Pharmaceticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	9.8M	12.9M	5.5M	10.5M	9.5M	9.0M
Other Current Liab	2.4M	1.2M	1.3M	5.0M	4.5M	2.5M
Total Current Liabilities	3.0M	1.8M	1.9M	5.6M	5.0M	3.8M
Total Stockholder Equity	6.7M	10.5M	3.2M	4.7M	4.2M	4.0M
Property Plant And Equipment Net	542K	1.2M	831K	571K	513.9K	488.2K
Net Debt	(7.3M)	(9.3M)	(2.2M)	(5.5M)	(6.3M)	(6.6M)
Retained Earnings	(122.4M)	(127.8M)	(135.3M)	(144.8M)	(130.3M)	(123.8M)
Accounts Payable	337K	485K	339K	314K	282.6K	268.5K
Cash	7.5M	10.1M	2.8M	6.0M	5.4M	8.0M
Non Current Assets Total	542K	1.2M	837K	3.5M	3.2M	3.0M
Non Currrent Assets Other	2.6M	(542K)	(1.2M)	(837K)	(753.3K)	(715.6K)
Cash And Short Term Investments	7.5M	10.1M	2.8M	6.0M	5.4M	8.0M
Non Current Liabilities Total	110K	619.5K	463K	295K	265.5K	252.2K
Other Current Assets	258K	607K	376K	355K	319.5K	303.5K
Other Stockholder Equity	74.4M	85.2M	83.7M	86.7M	99.7M	59.2M
Total Liab	3.1M	2.5M	2.4M	5.9M	5.3M	5.8M
Total Current Assets	9.3M	11.8M	4.7M	7.0M	6.3M	10.0M
Intangible Assets	10.1M	10.1M	6K	2.9M	2.6M	2.5M
Short Long Term Debt Total	260K	766K	624K	464K	417.6K	396.7K
Net Receivables	95K	33K	329K	704K	633.6K	455.7K
Liabilities And Stockholders Equity	9.8M	12.9M	5.5M	10.5M	9.5M	9.0M
Accumulated Other Comprehensive Income	53.7M	53.5M	53.0M	61.5M	70.8M	53.6M
Short Term Debt	200K	146K	161K	169K	152.1K	144.5K
Common Stock	63K	98.5K	1.1M	1.2M	1.4M	1.4M
Common Stock Shares Outstanding	5.4K	10.1K	12.4K	31.6K	36.3K	38.1K
Capital Lease Obligations	153K	766K	624K	464K	417.6K	504.3K
Net Invested Capital	6.8M	10.5M	3.2M	4.7M	4.2M	7.9M
Property Plant And Equipment Gross	2.1M	2.8M	2.5M	2.3M	2.1M	2.8M
Capital Stock	63K	98.5K	1.1M	1.2M	1.4M	1.4M
Net Working Capital	6.3M	9.9M	2.8M	1.5M	1.3M	1.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Biodexa Stock Analysis

When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Biodexa Historical Balance Sheet

Biodexa Pharmaceticals Inventory

(601,920)

About Biodexa Balance Sheet Analysis

Biodexa Pharmaceticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

Biodexa Pharmaceticals balance sheet Correlations

Biodexa Pharmaceticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Biodexa Pharmaceticals balance sheet Accounts

Also Currently Popular

Additional Tools for Biodexa Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Stockholder Equity	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash And Short Term Investments
Intangible Assets	+ 0.98	Non Current Assets Total
Non Current Assets Total	+ 0.96	Total Assets

Cash And Short Term Investments	- 0.97	Net Debt
Cash	- 0.97	Net Debt
Other Stockholder Equity	- 0.96	Retained Earnings
Total Current Assets	- 0.93	Net Debt
Other Assets	- 0.91	Retained Earnings
Short Term Debt	- 0.87	Other Stockholder Equity